Synendos Therapeuthics
Key Facts
| Invested since | 2020 |
| Based in | International |
About the company
Synendos is developing first-in-class inhibitors that modulate a newly identified drug target in the body’s endocannabinoid system, enabling restoration of endogenous cannabinoid levels that are suppressed in certain pathological conditions. The endocannabinoid system is a key neuromodulator system in the CNS involved in regulating various physiological and cognitive processes. Synendos’ newly developed selective endocannabinoid reuptake inhibitors (SERIs) act by increasing the levels of endogenous cannabinoids in a self-limiting mode of action, representing an innovative and potentially safer therapeutic approach to CNS disorders associated with anxiety, mood and stress-related disorders.
Do you want to
know more about this company?
Synendos Therapeuthics in the news
More startups from Life Sciences
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. Our goal is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a …
To the complete profileof Tubulis
Alentis Therapeutics discovers and develops novel medications to treat advanced liver diseases, such as liver fibrosis, cirrhosis and liver cancer (hepatocellular carcinoma, HCC). Alentis has in-licensed platform technologies and monoclonal …
To the complete profileof Alentis
Lindis Blood Care is developing a medical device to be used in oncology for the operation of tumours in order to open up the possibility of self-blood administration of blood …
To the complete profileof Lindis Blood Care
stimOS develops and markets (r)evolutionary technologies that functionalize implant materials and offers these technologies to implant manufacturers. With the product lines spineFuse and smartDENT the company develops own biosimilar implant …
To the complete profileof stimOS
Senostic is a diagnostics company developing a differential diagnostic test to detect multiple neurodegenerative diseases in a single test based on its proprietary SeedCylcer platform technology.
To the complete profileof SeNostic
TolerogenixX GmbH has developed a patented and clinically tested cell therapy technique for individualised immunosuppression in transplant patients. The technique enables the targeted disabling of undesired reactions caused by the …
To the complete profileof TolerogenixX
Exit
lino Biotech AG was incorporated as a ETH Zurich spin-out in Zürich, Switzerland, in March 2020, and is venture backed by Roche Venture Fund, High-Tech Gründerfonds and several lifescience family …
To the complete profileof Lino Biotech
Treatment of sustainable plaque in coronary arteries through our proprietary catheter based device.
To the complete profileof Cryotherapeutics
Innerspace develops novel, psychologically based training solutions for highly critical applications in the life science industry. Cleanroom operators are comprehensively prepared for the key moments of their work using the …
To the complete profileof innerspace
Exit
Cardior is focused on the development and clinical validation of ncRNA therapeutics for patients with myocardial infarction and heart failure. Cardior aims to market its products in collaboration with a …
To the complete profileof CARDIOR
Exit
SIRION BIOTECH produces genetically modified cells and is technology provider in the area of viral vector systems. The specialist in RNAi technology distributes more than 100 products and services. A …
To the complete profileof SIRION Biotech
Exit
KSK Diagnostics GmbH uses its isothermal amplification technology, KDx rITA®, for the development of molecular point-of-care tests to identify pathogens and antimicrobial resistance within 30 minutes. This significantly reduces the …
To the complete profileof KSK Diagnostics